Clinical trials: for Brain Tumors
Brain Tumors, Metastatic Disease
Donepezil in Treating Patients Who Have Undergone Radiation Therapy for Brain Tumors
RATIONALE: Donepezil may help lessen confusion and fatigue and improve mood and quality of life in patients who have undergone radiation therapy for brain tumors.
- Trial name
- NCT00369785
- Testing
- donepezil hydrochloride
- Where
- 16 sites in United States
- Volunteers
- 198 people
- Sponsor
- Wake Forest University Health Sciences
Neurofibromatosis Type 1, Recurrent Childhood Brain Stem Glioma
Pomalidomide in Treating Younger Patients With Recurrent, Progressive, or Refractory Central Nervous System Tumors
This phase I trial studies the side effects and best dose of pomalidomide in treating younger patients with tumors of the brain or spine (central nervous system) that have come back or are continuing to grow.
- Conditions
- Neurofibromatosis Type 1, Recurrent Childhood Brain Stem Glioma, Recurrent Childhood Visual Pathway Glioma, Recurrent Primary Central Nervous System Neoplasm
- Trial name
- NCT02415153
- Testing
- Laboratory Biomarker Analysis, Pharmacological Study, Pomalidomide
- Where
- 12 sites in United States
- Volunteers
- 29 people
- Sponsor
- National Cancer Institute (NCI)
Prostate Cancer, Mild Cognitive Impairment
PET Imaging in MCI Following ADT for PCa
Mild cognitive impairment (MCI) with ageing is thought in part to be related to reduced serum sex hormones which is well-recognized, especially in females, but poorly understood.
- Trial name
- NCT02061345
- Where
- United Kingdom
- Volunteers
- 11 people
- Sponsor
- Imperial College London
Non-small Cell Lung Cancer (NSCLC), EGFR Mutation-Positive Lung Cancer
Evaluation of the Efficacy and Safety of Befotertinib Combined With Bevacizumab as First-Line Treatment for EGFR-Positive Non-Small Cell Lung Cancer With Brain Metastases: A Single-Arm, Open-Label, Prospective Phase II Clinical Study
This study evaluates the safety and efficacy of Befotertinib combined with Bevacizumab as a first-line treatment for patients with EGFR mutation-positive advanced non-small cell lung cancer (NSCLC) accompanied by brain or…
- Conditions
- Non-small Cell Lung Cancer (NSCLC), EGFR Mutation-Positive Lung Cancer, Brain Metastases, Leptomeningeal Metastases
- Trial name
- Better Brain (NCT06728865)
- Testing
- The treatment regimen is Befotertinib combined with Bevacizumab.
- Where
- China
- Volunteers
- 70 people
- Sponsor
- Li-kun Chen
Breast Cancer With Brain Metastases
Pyrotinib Combined With Capecitabine and Bevacizumab for Patients With HER2 Positive Breast Cancer and Brain Metastases
This study intends to conduct a small, prospective, single-center clinical study to explore and evaluate the efficacy and safety of pyrrotinib combined with capecitabine and bevacizumab in HER2-positive advanced breast cancer…
- Trial name
- NCT06152822
- Testing
- pyrotinib+capecitabine+bevacizumab
- Where
- China
- Volunteers
- 30 people
- Sponsor
- Tongji Hospital
Astrocytoma, Glioma
Phase II Study of Irinotecan HCI for Recurrent Anaplastic Astrocytomas, Mixed Malignant Gliomas, and Oligodendrogliomas
Phase 2 trial to explore the efficacy and safety of irinotecan (CPT-11). Also administered at each cycle was zofran/Kytril/Anzemet, decadron, and IV atropine.
- Conditions
- Astrocytoma, Glioma, Oligodendroglioma
- Trial name
- NCT00360828
- Testing
- Irinotecan Hydrochloride (HCI) Treatment, Continued Irinotecan Hydrochloride (HCI) Treatment
- Where
- United States
- Volunteers
- 10 people
- Sponsor
- H. Lee Moffitt Cancer Center and Research Institute
Brain Tumor
CONVIVO System to Discriminate Healthy Tissues vs Tumor Tissues During Brain Tumor Resection
The purpose of the study is to do a direct comparison of the CONVIVO system (camera imaging device) with our normal Stanford pathology process.
- Trial name
- NCT05247749
- Testing
- CONVIVO Confocal Endomicroscopy System
- Sponsor
- Stanford University
NSCLC, Brain Metastases
A Dose Exploration Study of Almonertinib for EGFRm NSCLC Patients With Brain/Leptomeningeal Metastasis (ARTISTRY)
Almonertinib is a three-generation epidermal growth factor receptor tyrosine kinase inhibitor(EGFR-TKI), which has shown competitive potential in the second-line treatment against first-generation TKIs.
- Conditions
- NSCLC, Brain Metastases, Leptomeningeal Metastasis
- Trial name
- NCT04778800
- Testing
- almonertinib, LM-first line treatment, LM-second line treatment
- Where
- China
- Volunteers
- 60 people
- Sponsor
- Henan Cancer Hospital
Glioma of Brain, Craniopharyngioma
Memantine for Prevention of Cognitive Late Effects in Pediatric Patients Receiving Cranial Radiation Therapy for Localized Brain Tumors
Children with brain tumors who have had radiation therapy are at risk for problems with attention, memory, and problem solving. Such problems may cause difficulty in school and daily life.
- Conditions
- Glioma of Brain, Craniopharyngioma, Ependymoma, Germ Cell Tumor
- Trial name
- NCT03194906
- Testing
- Memantine, Cognitive Assessment
- Where
- United States
- Volunteers
- 41 people
- Sponsor
- St. Jude Children's Research Hospital
Brain Tumors
Blood Flow MRI for Monitoring Brain Tumors
The investigators are studying the use of an advanced magnetic resonance imaging (MRI) technique for measuring blood flow into brain tumors.
- Trial name
- Glioma (NCT01538264)
- Where
- United States
- Volunteers
- 125 people
- Sponsor
- Beth Israel Deaconess Medical Center
Brain Metastasis
Evaluation of the Use of Trental and Vitamin E For Prophylaxis of Radiation Necrosis
The purpose of this study is to determine whether the use of Trental and Vitamin E can help reduce the incidence of radiation necrosis (a lesion that usually occurs at the original tumor site) after radiosurgery.
- Trial name
- NCT01508221
- Testing
- Trental, Vitamin E
- Where
- United States
- Volunteers
- 31 people
- Sponsor
- University of Cincinnati
Brain Cancer, Breast Cancer
18-F-Fluoroacetate as PET Imaging Agent
The goal of this clinical research study is to find out the highest tolerable dose of an imaging solution called 18-F-fluoroacetate sodium that can be given before a positron emission tomography (PET) scan.
- Conditions
- Brain Cancer, Breast Cancer, Prostate Cancer
- Trial name
- NCT01320787
- Testing
- 18F-fluoroacetate
- Sponsor
- M.D. Anderson Cancer Center
Brain Tumor, Pediatric, Cancer-related Fatigue
Methylphenidate in Pediatric Brain Tumor Survivors With Cancer-related Fatigue
Cancer-related fatigue is a common and debilitating late effect in pediatric brain tumor survivors. Currently, evidence-based recommendations to ameliorate this condition are lacking.
- Conditions
- Brain Tumor, Pediatric, Cancer-related Fatigue, Methylphenidate
- Trial name
- EMBRAIN (NCT06905587)
- Testing
- Methylphenidate (MPH)
- Where
- 4 sites in Denmark
- Volunteers
- 50 people
- Sponsor
- Odense University Hospital
Stroke, Traumatic Brain Injury
Targeting Osteosarcopaenia and Multimorbidity for Frailty Prevention
The aging population and its accompanying burden from non-communicable chronic diseases predicts an increasing impact imposed by frailty on healthcare systems.
- Conditions
- Stroke, Traumatic Brain Injury, Knee Osteoarthritis, Breast Cancer
- Trial name
- OPTIMA-C (NCT06073106)
- Where
- Singapore
- Volunteers
- 500 people
- Sponsor
- Tan Tock Seng Hospital
Metastatic Malignant Neoplasm to the Adult Brain
Robotic Compared to Fixed Gantry Radiosurgery for Brain Metastases
Radiosurgery is precisely delivered high dose radiation. It can be performed using multiple cobalt sources, a modified traditional gantry-based linear accelerator or a robotic linear accelerator.
- Trial name
- TRICK (NCT01353573)
- Testing
- Fixed Gantry Radiosurgery, Robotic Radiosurgery
- Where
- Canada
- Volunteers
- 60 people
- Sponsor
- Hamilton Health Sciences Corporation
Supratentorial Neoplasms
Mannitol Brain Relaxation Effect
Mannitol is widely used in patients with elevated intracranial pressure. In neurosurgical field, especially in large size or with brain edema, it is necessary to decrease brain volume to facilitate surgical approach.
- Trial name
- MANNITOL (NCT02168075)
- Testing
- 0.25g/kgof 20% mannitol, 0.5g/kg of 20% mannitol, 1.0g/kg of 20% mannitol
- Where
- South Korea
- Volunteers
- 124 people
- Sponsor
- Seoul National University Hospital
Hyponatremia, Syndrome of Inappropriate ADH (SIADH) Secretion
An Observational Study Measuring Outcomes in Cancer Patients Treated for Moderate to Severe Hyponatremia in Italy
This observational, prospective, non-interventional study will include cancer patients who need a treatment for hyponatraemia secondary to SIADH.
- Conditions
- Hyponatremia, Syndrome of Inappropriate ADH (SIADH) Secretion, Cancer
- Trial name
- ASSERT (NCT02573077)
- Where
- 20 sites in Italy
- Volunteers
- 69 people
- Sponsor
- Otsuka Pharmaceutical Europe Ltd
Brain Tumor, Brain Tumor, Recurrent
Evaluation of LY2606368 Therapy in Combination With Cyclophosphamide or Gemcitabine for Children and Adolescents With Refractory or Recurrent Group 3/Group 4 or SHH Medulloblastoma Brain Tumors
SJELIOT is a phase 1 trial that aims to explore the combination of prexasertib with established DNA-damaging agents used in medulloblastoma to evaluate tolerance and pharmacokinetics in recurrent or refractory disease.
- Conditions
- Brain Tumor, Brain Tumor, Recurrent, Brain Tumor, Refractory, Brain Tumor, Pediatric
- Trial name
- NCT04023669
- Testing
- Prexasertib, Cyclophosphamide, Gemcitabine
- Where
- United States
- Volunteers
- 21 people
- Sponsor
- St. Jude Children's Research Hospital
Brain Tumor, Recurrent, Malignant Glioma (WHO Grade III or IV)
Chronic CED of TPT for Recurrent Malignant Glioma
The primary goal of this study is to establish the safety of chronic Convection Enhanced Delivery (CED) of the chemotherapeutic drug Topotecan for patients with recurrent malignant glioma that harbors the Isocitrate Dehydrogenase…
- Conditions
- Brain Tumor, Recurrent, Malignant Glioma (WHO Grade III or IV), IDH1/IDH2 Mutation
- Trial name
- TPT CED rHGG (NCT06666712)
- Testing
- Topotecan
- Where
- United States
- Volunteers
- 6 people
- Sponsor
- Jeffrey N. Bruce
Adult Giant Cell Glioblastoma, Adult Glioblastoma
Cilengitide in Treating Patients Who Are Undergoing Surgery for Recurrent or Progressive Glioblastoma Multiforme
Cilengitide may stop the growth of glioblastoma multiforme by blocking blood flow to the tumor. Giving cilengitide before and after surgery may be an effective treatment for glioblastoma multiforme.
- Conditions
- Adult Giant Cell Glioblastoma, Adult Glioblastoma, Adult Gliosarcoma, Recurrent Adult Brain Tumor
- Trial name
- NCT00112866
- Testing
- cilengitide, therapeutic conventional surgery, pharmacological study
- Where
- United States
- Volunteers
- 30 people
- Sponsor
- National Cancer Institute (NCI)
The first 1,020 results can be paged through. Add a filter or change the sort order to reach the rest.